What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?

Rory McCulloch; Toby A Eyre; Simon Rule

doi:10.1016/j.hoc.2020.06.008

What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?

Hematol Oncol Clin North Am. 2020 Oct;34(5):923-939. doi: 10.1016/j.hoc.2020.06.008. Epub 2020 Aug 5.

Authors

Rory McCulloch¹, Toby A Eyre², Simon Rule³

Affiliations

¹ Department of Haematology, Peninsula Medical School, University of Plymouth, Plymouth, UK.
² Department of Haematology, Oxford University Hospitals, Oxford, UK.
³ Department of Haematology, Peninsula Medical School, University of Plymouth, John Bull Building, Plymouth PL6 8BU, UK. Electronic address: [email protected].

PMID: 32861287
DOI: 10.1016/j.hoc.2020.06.008

Abstract

In this review, we explore insights into the pathophysiology of Bruton tyrosine kinase inhibitor (BTKi) resistance in mantle cell lymphoma, and consider potential therapeutic targets. We review the possible clinical benefits of giving BTKis alongside other novel therapies, and evaluate clinical data for treatment strategies post BTKi progression that may help guide current practice. We conclude by considering future approaches, including the potential role of chimeric antigen receptor T-cell therapy.

Keywords: Bruton tyrosine kinase inhibitor; Chimeric antigen receptor T-cell therapy; Mantle cell lymphoma; Resistance mechanisms.

Publication types

Review

MeSH terms

Agammaglobulinaemia Tyrosine Kinase* / antagonists & inhibitors
Agammaglobulinaemia Tyrosine Kinase* / genetics
Agammaglobulinaemia Tyrosine Kinase* / metabolism
Drug Resistance, Neoplasm*
Humans
Immunotherapy, Adoptive*
Lymphoma, Mantle-Cell* / enzymology
Lymphoma, Mantle-Cell* / genetics
Lymphoma, Mantle-Cell* / therapy
Protein Kinase Inhibitors / therapeutic use*

Substances

Protein Kinase Inhibitors
Agammaglobulinaemia Tyrosine Kinase
BTK protein, human